Fig. 5From: Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA®): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal riskPrognosis of CKD in the CARMELINA® trial population by eGFR and albuminuria categories.*CKD chronic kidney disease, eGFR estimated glomerular filtration rate, KDIGO Kidney Disease: Improving Global Outcomes, UACR urinary albumin-to-creatinine ratioBack to article page